Abstract
Purpose To identify characteristics of SARS-CoV-2 infection that are associated with hospitalization in children initially evaluated in a Pediatric Emergency Department (ED).
Methods We identified cases of SARS-CoV-2 positive patients seen in the Arkansas Children’s Hospital (ACH) ED or hospitalized between May 27, 2020, and April 28, 2022 using ICD-10 codes within the Pediatric Hospital Information System (PHIS) Database. We compared infection waves for differences in patient characteristics, and used logistic regressions to examine which characteristics led to a higher chance of hospitalization.
Findings We included 681 pre-Delta cases, 673 Delta cases, and 970 Omicron cases. Almost 17% of patients were admitted to the hospital. Compared to Omicron infected children, pre-Delta and Delta infected children were twice as likely to be hospitalized (OR=2.2 and 2.0, respectively; p<0.0001). Infants less than 1 year of age were >3 times as likely to be hospitalized than children ages 5-14 years regardless of wave (OR=3.42; 95%CI=2.36–4.94). Rural children were almost 3 times as likely than urban children to be hospitalized across all waves (OR=2.73; 95%CI=1.97–3.78). Finally, those with a complex condition had nearly a 15-fold increase in odds of admission (OR=14.6; 95%CI=10.6–20.0).
Conclusions Children diagnosed during the pre-Delta or Delta waves were more likely to be hospitalized than those diagnosed during the Omicron wave. Younger and rural patients were more likely to be hospitalized regardless of wave. We suspect lower vaccination rates and larger distances from medical care influenced higher hospitalization rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Center for Translational Pediatric Research (NIH/NIGMS P20GM121293) at Arkansas Childrens Hospital, and by the Translational Research Institute (NIH/NCATS UL1TR003107) at the University of Arkansas for Medical Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UAMS IRB 262416 provided oversight for this project. We obtained waiver of consent and HIPAA authorization for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Source: This work was supported by the Center for Translational Pediatric Research (NIH/NIGMS P20GM121293) at Arkansas Childrens Hospital, and by the Translational Research Institute (NIH/NCATS UL1TR003107) at the University of Arkansas for Medical Sciences.
Financial Disclosure Statement: Dr. Joshua Kennedy, Mr. Eric Siegel, and Ms. Grace Turner, Ashton Ingold, Susanna Hartzell, Suzanne House, and Dana Frederick are supported by the Center for Translational Pediatric Research (NIH/NIGMS P20GM121293). Drs. Joshua Kennedy and Uday Chalwadi as well as Mr. Eric Siegel are supported by the Translational Research Institute (NIH/NCATS UL1TR003107).
Conflict of Interest Statement: Dr. Kennedy has been a consultant for Genentech for asthma. Funding organizations were not involved in the design or conduct of the study, nor were they involved in the collection, analysis, or interpretation of the data, nor were they involved in the preparation, editing, or censuring of the manuscript.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.